ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2010 Financial Results
July 28 2010 - 5:30AM
Business Wire
ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that
develops targeted anticancer products, today announced that the
Company will host a conference call at 4:30 p.m. ET on
Wednesday, August 4, 2010, to discuss ImmunoGen’s financial results
for the three-month period and fiscal year ended June 30, 2010.
Management also will provide an update on the Company.
To access the live call by phone, dial 913-312-0379. Passcode
4241333. The call also may be accessed through the Investor
Information section of the Company’s website, www.immunogen.com.
Following the live webcast, a replay of the call will be available
at the same location through August 11, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
its expertise in cancer biology, monoclonal antibodies and the
creation and attachment of potent cancer-cell killing agents. The
Company’s Targeted Antibody Payload (TAP) technology uses
engineered antibodies to deliver one of ImmunoGen’s proprietary
cancer-cell killing agents specifically to tumor targets. In
addition to the Company’s product pipeline, compounds are in
clinical testing through ImmunoGen’s collaborations with Genentech
(a member of the Roche Group), sanofi-aventis, Biogen Idec and
Biotest. A marketing application for the most advanced compound
using ImmunoGen’s TAP technology, T-DM1, was submitted to the US
FDA by Genentech in July 2010. Other ImmunoGen collaborative
partners include Bayer Schering Pharma AG and Amgen. More
information about ImmunoGen can be found at www.immunogen.com.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024